About ConcertAI
ConcertAI is a healthcare AI company that orchestrates clinical expertise, real-world data, and applied artificial intelligence to deliver practical intelligence for oncology and other complex diseases. The company operates across the healthcare ecosystem, serving life sciences and pharmaceutical companies, healthcare systems, oncology practices, and enterprise imaging departments. ConcertAI's platform integrates over 13 million de-identified patient records through its CancerLinQ network, providing comprehensive coverage for both solid and hematologic cancers with weekly data updates. The company's solutions span four primary areas: Real-World Evidence (Precision360, Precision Explorer, Translational360, Patient360), Clinical Trials (ACT, TriaLinQ), Commercial Intelligence (Cadence Suite, Data Foundry, Precision GTM), and Enterprise Imaging through its TeraRecon division (Advanced Visualization, Imaging Workflows, DETECT, AI Framework). ConcertAI's AI-driven approach has been used in over 500 peer-reviewed publications and is built by a team of hundreds of advanced degree-holders and data scientists. The company works with 75% of the top 30 life sciences companies and approximately 50% of the top 250 global healthcare systems. ConcertAI's technology partners include NVIDIA and AWS, while laboratory partnerships include Caris, Guardant, Foundation Medicine, and NeoGenomics. The company's mission centers on supporting high-stakes decisions in tight timelines, from research to treatment to delivery, helping organizations move from fragmented data to confident decisions that advance care in complex diseases.
Clinical Focus
Medical conditions and clinical areas addressed by ConcertAI.
Who It Serves
Milestones & Awards
Recent Milestones
CancerLinQ suite expanded with AI-driven trial matching. CancerLinQ network announced expansion to new clinical sites. ConcertAI announced Cadence Suite for full visibility into patient treatment journey.
Awards & Recognition
ConcertAI Named One of Fast Company's Most Innovative Companies of 2026. Featured in Frost & Sullivan's Frost Radar for AI in Clinical Trials.
Key Partnerships
Social & Media
Latest Updates
From Orchestration to Discovery: ConcertAI, NVIDIA, and What Comes Next with BioNeMo
3w ago
Building the Trustworthy Data Foundation for Healthcare AI
1mo ago
Precision360’s weekly curation powers new possibility
1mo ago
AI In Clinical Trials: From Promise To Measurable Impact
2mo ago
Translational360 for Decision-Ready Evidence | ConcertAI
2mo ago
Company Details
- Founded
- 2017
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.